妊娠晚期利匹韦林暴露降低:一项HIV-1感染孕妇的药代动力学研究
这项非随机、开放标签、多中心4期研究纳入16例每日服用利匹韦林25 mg的HIV-1感染孕妇,比较妊娠晚期与产后至少2周的24小时药代动力学。妊娠晚期AUC0-24h、峰浓度和Cmin的几何均值比分别为0.55、0.65和0.51,4例(25%)Cmin低于目标浓度0.04 mg/L,但病毒抑制维持且无母婴传播。
要点
- 妊娠晚期利匹韦林暴露显著降低,Cmin几何均值仅为产后的0.51倍。
- 16例中4例(25%)妊娠晚期Cmin低于0.04 mg/L目标浓度。
- 暴露降低下仍维持病毒学抑制,未观察到母婴传播或出生缺陷。
核心结论
- 妊娠晚期利匹韦林暴露显著降低,但病毒学抑制维持且未观察到围产期传播。
- 每日利匹韦林25 mg或可作为病毒学已抑制孕妇的替代选择,前提是可进行治疗药物监测和/或密切病毒载量监测。
研究设计与样本
- 非随机、开放标签、多中心4期药代动力学研究。
- 纳入16例每日服用利匹韦林25 mg的HIV-1感染孕妇,在妊娠晚期和产后至少2周进行24小时密集药代动力学采样,采用非房室分析计算参数。
主要发现
- 妊娠晚期与产后几何均值比:AUC0-24h为0.55(90%CI .46-.66),峰浓度为0.65(90%CI .55-.76),Cmin为0.51(90%CI .41-.63)。
- 16例中4例(25%)妊娠晚期Cmin低于目标浓度0.04 mg/L,产后未观察到亚治疗水平。
- 研究期间未检测到病毒载量,所有新生儿HIV检测阴性,未报告出生缺陷。
- 脐带血与母体血浆利匹韦林浓度比中位数为0.50(范围.35-.81,n=5)。
关键数值与推荐
- 目标Cmin为0.04 mg/L,妊娠晚期4/16(25%)受试者低于该值。
- 妊娠晚期与产后几何均值比:AUC0-24h 0.55(90%CI .46-.66)、峰浓度0.65(90%CI .55-.76)、Cmin 0.51(90%CI .41-.63)。
- 脐带血与母体血浆浓度比中位数0.50(范围.35-.81,n=5)。
临床怎么用
- 对病毒学已抑制的HIV-1感染孕妇,利匹韦林25 mg每日一次可作为替代方案。
- 使用时应确保可进行治疗药物监测和/或密切病毒载量监测,以及时发现抗逆转录病毒治疗亚优化。
局限性
- 研究为非随机、开放标签设计,样本量16例较小。
- 未设对照臂,产后比较为自身对照,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of antiretroviral therapy during pregnancy is important for control of maternal human immunodeficiency virus (HIV) disease and the prevention of perinatal HIV transmission. Physiological changes during pregnancy can reduce antiretroviral exposure. We studied the pharmacokinetics of rilpivirine 25 mg once daily in HIV-1-infected women during late pregnancy. METHODS: We conducted a nonrandomized, open-label, multicenter, phase 4 study. HIV-infected pregnant women receiving rilpivirine 25 mg once daily were included. Intensive 24-hour pharmacokinetic sampling was performed in the third trimester and at least 2 weeks postpartum. Pharmacokinetic parameters were calculated by noncompartmental analysis. RESULTS: Sixteen subjects were included. Geometric mean ratios of third trimester vs postpartum were 0.55 (90% confidence interval [CI], .46-.66) for the 24-hour area under the concentration-time curve (AUC0-24h); 0.65 (90% CI, .55-.76) for the maximum concentration; and 0.51 (90% CI, .41-.63) for the minimum observed concentration (Cmin). Four of 16 (25%) subjects had Cmin below the target concentration (0.04 mg/L) in the third trimester of pregnancy. No subtherapeutic levels were observed postpartum. No detectable viral loads were observed in this study. All newborns tested negative for HIV. No birth defects were reported. The median (range, n = 5) rilpivirine cord-to-maternal plasma concentration ratio was 0.50 (range, .35-.81). CONCLUSIONS: Rilpivirine exposure is substantially lowered during late pregnancy. Despite lower exposure, virologic suppression was maintained and no perinatal transmission was observed. Overall, these results suggest that rilpivirine 25 mg once daily may be an alternative treatment option for HIV-1-infected pregnant women who are virologically suppressed, in settings where therapeutic drug monitoring and/or close viral load monitoring are feasible to detect suboptimal antiretroviral therapy. CLINICAL TRIALS REGISTRATION: NCT00825929.
引用
- Schalkwijk S, Colbers A, Konopnicki D, et al. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. Clin Infect Dis. 2017. PMID: 28595298. doi:10.1093/cid/cix534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。